



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
-----------------	-------------	----------------------	---------------------	------------------

10/781,984

02/18/2004

Evgenia Mandrusov

5618P2926D

5727

45215

7590

06/04/2010

ABBOTT CARDIOVASCULAR SYSTEMS INC./BSTZ  
BLAKELY SOKOLOFF TAYLOR & ZAFMAN LLP  
1279 OAKMEAD PARKWAY  
SUNNYVALE, CA 94085-4040

EXAMINER

SMITH, RUTH S

ART UNIT

PAPER NUMBER

3737

MAIL DATE

DELIVERY MODE

06/04/2010

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

<b>Office Action Summary</b>	<b>Application No.</b> 10/781,984	<b>Applicant(s)</b> MANDRUSOV ET AL.	
	<b>Examiner</b> Ruth S. Smith	<b>Art Unit</b> 3737	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

#### Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) ☒ Responsive to communication(s) filed on 09 March 2010.
- 2a) ☐ This action is **FINAL**.                      2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) ☒ Claim(s) 1,3-14,32 and 38-54 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1,3-14,32 and 38-54 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

#### Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All    b) ☐ Some \*    c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)            | 4) <input type="checkbox"/> Interview Summary (PTO-413)           |
| 2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948)    | Paper No(s)/Mail Date. _____                                      |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date _____  | 6) <input type="checkbox"/> Other: _____                          |

***Claim Objections***

Claims 48 and 53 are objected to because of the following informalities: In the claims, line 1, the term "needle" is misspelled. Appropriate correction is required.

***Claim Rejections - 35 USC § 102***

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1,3,5-9,12,14,38-40,48,53 are rejected under 35 U.S.C. 102(e) as being anticipated by Makower et al (6,602,241). The claims are directly readable on Makower et al which disclose a method of delivering substances to extravascular treatment sites. The method includes advancing a catheter into a blood vessel and imaging 360 degrees about the vessel wall to locate a treatment site. The catheter is then advanced through the vessel wall to deliver a treatment agent to a target site. The treatment agent can include a sustained release composition in a carrier (col 16, lines 50-67, col 17, lines 1-5). The treatment agent can include an inflammation-inducing agent directed to a specific binding site to stimulate angiogenesis (col 1-2). Imaging of the vessel wall would inherently include imaging a thickness of at least a portion of a wall of the blood vessel. The imaging transducer is located in a lumen of the catheter and can include an ultrasound imaging device. The device is advanced through the vessel wall to an extravascular treatment site and therefore would provide the treatment site as set forth in claims 5,6. The use of Makower et al would include treatment sites as set forth in claims 7,8. The catheter includes a flexible needle

Art Unit: 3737

device for penetrating the vessel wall. The device is considered be a “ribbon member deflector” which deflects the tip of the needle.

***Claim Rejections - 35 USC § 103***

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 4,32,54 are rejected under 35 U.S.C. 103(a) as being unpatentable over Makower et al in view of Selmon et al (6,514,217). Makower et al disclose the invention as discussed above but fails to disclose the use of optical imaging such as OCT. Makower et al disclose that other types of imaging devices can be used instead of ultrasound. The use of both ultrasound and OCT are well known in the art for imaging blood vessels as seen for example in Selmon et al. It would have been obvious to one skilled in the art to have modified Makower et al such that the imaging modality used is OCT. Such a modification merely involves the substitution of one known type of imaging modality for another.

Claims 7,8,10-13,41-43,46,47,51,52 are rejected under 35 U.S.C. 103(a) as being unpatentable over Makower et al. Makower et al disclose the invention as discussed above but fails to specifically disclose the treatment sites as set forth in claims 7,8 or the agents/carriers as set forth in claims 10-13,41-43,46,47,51,52. The use of the device for any known treatment site in the body would have been obvious to one skilled in the art given the disclosed agents provided by Makower et al. With respect to claim 10, in the absence of any showing of criticality, the specific size of the carrier used would have been an obvious design choice of known equivalents in the art. With respect to claims 11-13,41-43,46,47,51,52 in the absence of any showing of criticality, the specific type of drug delivered would have been an obvious selection based upon the desired patient treatment.

Claim 11 is rejected under 35 U.S.C. 103(a) as being unpatentable over Makower et al in view of Segal (2002/0131974). Makower et al disclose the invention as discussed above but fails to specifically disclose the use of an opsonin-inhibitor. The use of an opsonin-inhibitor is known in order to modulate the response to carriers put into a subject for treatment purposes. It would have been obvious to one skilled in the art to have modified Makower et al such that the carrier includes an opsonin-inhibitor as is a well known expedient in the art of drug delivery.

Claims 12, 13,41,42,43,47,52 are rejected under 35 U.S.C. 103(a) as being unpatentable over Makower et al in view of Slepian et al (5,749,915). Makower et al disclose the invention as discussed above but fails to specifically disclose the agents set forth in claims 12,13,41,42,43,47,52 above. The use of materials such as polycaprolactone and polyurethane for treatments involving blood vessels are known as taught by Slepian et al and the use of such known materials would have been obvious. The materials can be incorporated into carriers for delivery such as nanoparticles or liposomes and can include other

Art Unit: 3737

particles such as metallic particles. The materials can be inflammation inducing and are heated when introduced into the body. It would have been obvious to one skilled in the art to have modified Makower et al such that materials, such as polycaprolactone and polyurethane in carriers such as metallic particles are used to further treat the vessels as is a well known expedient in the art.

Claims 44-45,49,50 are rejected under 35 U.S.C. 103(a) as being unpatentable over Makower et al in view of Yock (5,676,151) or Ouchi (6,338,717). Makower et al disclose the invention as discussed above but fails to specifically disclose the use of a balloon through which the imaging occurs. It is a well known expedient in the art to provide a balloon at the end of a device placed in the body in order to the device to be fixed at a desired location. Examples of medical devices which include a balloon at the tip of the device and an imaging means which images through a transparent material of the balloon is shown in Yock and Ouchi. It would have been obvious to one skilled in the art to have modified Makower et al such that the catheter includes a balloon through which the imaging occurs as such is a well known expedient for positioning a catheter in the body for diagnosis or treatment.

### ***Response to Arguments***

Applicant's arguments with respect to claims 1,3-14,32,38-54 have been considered but are moot in view of the new ground(s) of rejection.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ruth S. Smith whose telephone number is 571-272-4745. The examiner can normally be reached on M-F 7:30 AM-4:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brian Casler can be reached on 571-272-4956. The fax

Art Unit: 3737

phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Ruth S. Smith/  
Primary Examiner, Art Unit 3737

RSS